DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Clement, B.
Right arrow Articles by Lopian, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Clement, B.
Right arrow Articles by Lopian, K.

Vol. 31, Issue 5, 645-651, May 2003

Characterization of in Vitro Biotransformation of New, Orally Active, Direct Thrombin Inhibitor Ximelagatran, an Amidoxime and Ester Prodrug

Bernd Clement and Katrin Lopian

Pharmaceutical Institute, Christian-Albrechts-University of Kiel, Kiel, Germany

N-Hydroxylated amidines (amidoximes) can be used as prodrugs of amidines. The prodrug principle was developed in our laboratory for pentamidine and had been applied to several other drug candidates. One of these compounds is melagatran, a novel, synthetic, low molecular weight, direct thrombin inhibitor. To increase the poor oral bioavailability due to its strong basic amidine functionality selected to fit the arginine side pocket of thrombin, the less basic N-hydroxylated amidine was used in addition to an ethyl ester-protecting residue. The objective of this investigation was to study the reduction and the hydrolytic metabolism of ximelagatran via two mono-prodrugs (N-hydroxy-melagatran and ethyl-melagatran) to melagatran by in vitro experiments. New high-performance liquid chromatography methods were developed to analyze all four compounds. The biotransformation of ximelagatran to melagatran involving the reduction of the amidoxime function and the ester cleavage could be demonstrated in vitro by microsomes and mitochondria from liver and kidney of pig and human, and the kinetic parameters were determined. So far, one enzyme system capable of reducing N-hydroxylated structures has been identified in pig liver microsomes, consisting of cytochrome b5, NADH-cytochrome b5 reductase, and a P450 isoenzyme of the subfamily 2D. This enzyme system also reduces ximelagatran and N-hydroxy-melagatran. The participation of recombinant human CYP1A2, 2A6, 2C8, 2C9, 2C19, 2D6, and 3A4 with cytochrome b5 and b5 reductase in the reduction can be excluded. In summary, ximelagatran and N-hydroxy-melagatran are easily reduced by several enzyme systems located in microsomes and mitochondria of different organs.

Copyright © 2003 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
E. Sjogren, H. Lennernas, T. B. Andersson, J. Grasjo, and U. Bredberg
The Multiple Depletion Curves Method Provides Accurate Estimates of Intrinsic Clearance (CLint), Maximum Velocity of the Metabolic Reaction (Vmax), and Michaelis Constant (Km): Accuracy and Robustness Evaluated through Experimental Data and Monte Carlo Simulations
Drug Metab. Dispos., January 1, 2009; 37(1): 47 - 58.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
E. Sjodin, H. Fritsch, U. G. Eriksson, U. Logren, A. Nordgren, P. Forsell, L. Knutson, and H. Lennernas
Intestinal and Hepatobiliary Transport of Ximelagatran and Its Metabolites in Pigs
Drug Metab. Dispos., August 1, 2008; 36(8): 1519 - 1528.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. Blech, T. Ebner, E. Ludwig-Schwellinger, J. Stangier, and W. Roth
The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans
Drug Metab. Dispos., February 1, 2008; 36(2): 386 - 399.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Havemeyer, F. Bittner, S. Wollers, R. Mendel, T. Kunze, and B. Clement
Identification of the Missing Component in the Mitochondrial Benzamidoxime Prodrug-converting System as a Novel Molybdenum Enzyme
J. Biol. Chem., November 17, 2006; 281(46): 34796 - 34802.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
J. Y. Saulter, J. R. Kurian, L. A. Trepanier, R. R. Tidwell, A. S. Bridges, D. W. Boykin, C. E. Stephens, M. Anbazhagan, and J. E. Hall
UNUSUAL DEHYDROXYLATION OF ANTIMICROBIAL AMIDOXIME PRODRUGS BY CYTOCHROME b5 AND NADH CYTOCHROME b5 REDUCTASE
Drug Metab. Dispos., December 1, 2005; 33(12): 1886 - 1893.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
M. P. Gulseth
Ximelagatran: An orally active direct thrombin inhibitor
Am. J. Health Syst. Pharm., July 15, 2005; 62(14): 1451 - 1467.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. Andersson, Y. Hofmann, A. Nordling, X.-q. Li, S. Nivelius, T. B. Andersson, M. Ingelman-Sundberg, and I. Johansson
CHARACTERIZATION AND PARTIAL PURIFICATION OF THE RAT AND HUMAN ENZYME SYSTEMS ACTIVE IN THE REDUCTION OF N-HYDROXYMELAGATRAN AND BENZAMIDOXIME
Drug Metab. Dispos., April 1, 2005; 33(4): 570 - 578.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
W. E Dager, T. G Vondracek, B. A McIntosh, and E. A Nutescu
Ximelagatran: An Oral Direct Thrombin Inhibitor
Ann. Pharmacother., November 1, 2004; 38(11): 1881 - 1897.
[Abstract] [Full Text] [PDF]

Home page
 J CARDIOVASC PHARMACOL THERHome page
W. E. Dager
Ximelagatran: A New Antithrombotic Option in Atrial Fibrillation
Journal of Cardiovascular Pharmacology and Therapeutics, July 1, 2004; 9(3): 151 - 162.
[Abstract] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.